CT-121: Phase 3 Study of the Efficacy and Safety of Iptacopan (LNP023), an Oral Factor B Inhibitor, in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naïve to Complement Inhibitor Therapy

MLA

Bing Han, et al. “CT-121: Phase 3 Study of the Efficacy and Safety of Iptacopan (LNP023), an Oral Factor B Inhibitor, in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naïve to Complement Inhibitor Therapy.” Clinical Lymphoma Myeloma and Leukemia, vol. 21, Sept. 2021, p. S450. EBSCOhost, https://doi.org/10.1016/s2152-2650(21)01999-6.

APA

Bing Han, Yasutaka Ueda, Marion Dahlke, Antonio M. Risitano, Régis Peffault de Latour, Georgina Bermann, & Yu Cheng. (2021). CT-121: Phase 3 Study of the Efficacy and Safety of Iptacopan (LNP023), an Oral Factor B Inhibitor, in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naïve to Complement Inhibitor Therapy. Clinical Lymphoma Myeloma and Leukemia, 21, S450. https://doi.org/10.1016/s2152-2650(21)01999-6

Chicago

Bing Han, Yasutaka Ueda, Marion Dahlke, Antonio M. Risitano, Régis Peffault de Latour, Georgina Bermann, and Yu Cheng. 2021. “CT-121: Phase 3 Study of the Efficacy and Safety of Iptacopan (LNP023), an Oral Factor B Inhibitor, in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naïve to Complement Inhibitor Therapy.” Clinical Lymphoma Myeloma and Leukemia 21 (September): S450. doi:10.1016/s2152-2650(21)01999-6.